Tolera Therapeutics Receives $1,465,000 New Funding

  • Feed Type
  • Date
    5/15/2012
  • Company Name
    Tolera Therapeutics
  • Mailing Address
    350 E. Michigan Avenue Kalamazoo, MI 49007
  • Company Description
    Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune suppression / modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects. The company is focusing first on commercializing a therapeutic monoclonal antibody for the transplantation and oncology markets, while researching and developing related therapies for those suffering from autoimmune diseases such as diabetes (Type 1). The company owns an exclusive, worldwide license to its antibody technology, including chimeric and humanized clones, which has already undergone extensive research, development and human studies.
  • Website
    http://www.tolera.com
  • Transaction Type
    Debt
  • Transaction Amount
    $1,465,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.